


**Claims:**

1. A compound of the general formula I



wherein

X is O, S or CR<sup>11</sup>R<sup>12</sup>, wherein R<sup>11</sup> and R<sup>12</sup> independently are selected from H or C<sub>1-6</sub> alkyl;

Y is O or S;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are independently selected from hydrogen; halogen; cyano; nitro; C<sub>1-6</sub>-alk(en/yn)yl; C<sub>1-6</sub>-alk(en/yn)yloxy; C<sub>1-6</sub>-alk(en/yn)ylsulfanyl; hydroxy; hydroxy-C<sub>1-6</sub>-alk(en/yn)yl; halo-C<sub>1-6</sub>-alk(en/yn)yl; halo-C<sub>1-6</sub>-alk(en/yn)yloxy; C<sub>3-8</sub>-cycloalk(en)yl; C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl; acyl; C<sub>1-6</sub>-alk(en/yn)yloxycarbonyl; C<sub>1-6</sub>-alk(en/yn)ylsulfonyl; aryl optionally substituted with a halogen, cyano, nitro, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub>-alk(en/yn)yloxy, C<sub>1-6</sub>-alk(en/yn)ylsulfanyl, hydroxy, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl, halo-C<sub>1-6</sub>-alk(en/yn)yloxy, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, acyl, C<sub>1-6</sub>-alk(en/yn)yloxycarbonyl or C<sub>1-6</sub>-alk(en/yn)ylsulfonyl; monocyclic heteroaryl optionally substituted with a halogen, cyano, nitro, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub>-alk(en/yn)yloxy, C<sub>1-6</sub>-alk(en/yn)ylsulfanyl, hydroxy, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl, halo-C<sub>1-6</sub>-alk(en/yn)yloxy, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, acyl, C<sub>1-6</sub>-alk(en/yn)yloxycarbonyl or C<sub>1-6</sub>-alk(en/yn)ylsulfonyl; or -NR<sup>13</sup>R<sup>14</sup> wherein R<sup>13</sup> and R<sup>14</sup> independently are selected from hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub> alk(en/yn)yl or aryl, or R<sup>13</sup>

and R<sup>14</sup> together with the nitrogen form a 3-7-membered heterocyclic ring which optionally contains one further heteroatom selected from O, S or N;

R<sup>5</sup> is aryl or monocyclic heteroaryl, optionally substituted with a halogen, cyano,  
5 nitro, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub>-alk(en/yn)yoxy, C<sub>1-6</sub>-alk(en/yn)ylsulfanyl, hydroxy, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl, halo-C<sub>1-6</sub>-alk(en/yn)yoxy, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, acyl, C<sub>1-6</sub>-alk(en/yn)ylloxycarbonyl, C<sub>1-6</sub>-alk(en/yn)ylsulfonyl or -NR<sup>15</sup>R<sup>16</sup> wherein R<sup>15</sup> and R<sup>16</sup>  
10 independently are selected from hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl or aryl, or R<sup>15</sup> and R<sup>16</sup> together with the nitrogen form a 3-7-membered heterocyclic ring which optionally contains one further heteroatom selected from O, S or N;

R<sup>6</sup> is selected from H, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub>-alk(en/yn)yoxy, C<sub>1-6</sub>-alk(en/yn)ylsulfanyl or C<sub>3-8</sub>-cycloalk(en)yl, provided that when R<sup>6</sup> is selected from  
15 C<sub>1-6</sub>-alk(en/yn)yoxy, or C<sub>1-6</sub>-alk(en/yn)ylsulfanyl then X is CR<sup>11</sup>R<sup>12</sup>, wherein R<sup>11</sup> and R<sup>12</sup> independently are selected from H or C<sub>1-6</sub> alkyl;

R<sup>7</sup> and R<sup>8</sup> are independently selected from H, C<sub>1-6</sub>-alk(en/yn)yl or C<sub>3-8</sub>-cycloalk(en)yl;  
20

R<sup>9</sup> and R<sup>9'</sup> are independently selected from H, C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub>-alk(en/yn)ylsulfanyl-C<sub>1-6</sub>-alk(en/yn)yl or C<sub>3-8</sub>-cycloalk(en)yl; or

R<sup>6</sup> and R<sup>8</sup> together with the nitrogen form a saturated 3-7 membered heterocyclic ring,  
25 and R<sup>7</sup> is selected from H, C<sub>1-6</sub>-alk(en/yn)yl or C<sub>3-8</sub>-cycloalk(en)yl, and R<sup>9</sup> and R<sup>9'</sup> are independently selected from H, C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub>-alk(en/yn)ylsulfanyl-C<sub>1-6</sub>-alk(en/yn)yl or C<sub>3-8</sub>-cycloalk(en)yl; or

R<sup>7</sup> and R<sup>8</sup> together with the nitrogen form a saturated 3-7 membered heterocyclic ring,  
30 and R<sup>6</sup> is selected from H, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub>-alk(en/yn)yoxy, C<sub>1-6</sub>-alk(en/yn)ylsulfanyl or C<sub>3-8</sub>-cycloalk(en)yl, provided that when R<sup>6</sup> is selected from C<sub>1-6</sub>-alk(en/yn)yoxy or C<sub>1-6</sub>-alk(en/yn)ylsulfanyl then X is CR<sup>11</sup>R<sup>12</sup>, wherein R<sup>11</sup> and R<sup>12</sup> independently are selected from H or C<sub>1-6</sub> alkyl, and R<sup>9</sup> and R<sup>9'</sup> are independently

selected from H, C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub>-alk(en/yn)ylsulfanyl-C<sub>1-6</sub>-alk(en/yn)yl or C<sub>3-8</sub>-cycloalk(en)yl; or

R<sup>8</sup> and R<sup>9</sup> together with the nitrogen form a saturated 3-7 membered heterocyclic ring,  
5 and R<sup>6</sup> is selected from H, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub>-alk(en/yn)ylloxy, C<sub>1-6</sub>-alk(en/yn)ylsulfanyl or C<sub>3-8</sub>-cycloalk(en)yl, provided that when R<sup>6</sup> is selected from C<sub>1-6</sub>-alk(en/yn)ylloxy or C<sub>1-6</sub>-alk(en/yn)ylsulfanyl then X is CR<sup>11</sup>R<sup>12</sup>, wherein R<sup>11</sup> and R<sup>12</sup> independently are selected from H or C<sub>1-6</sub> alkyl, and R<sup>7</sup> is selected from H, C<sub>1-6</sub>-alk(en/yn)yl or C<sub>3-8</sub>-cycloalk(en)yl, and R<sup>9'</sup> is selected from H, C<sub>1-6</sub>-alk(en/yn)yl,  
10 hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub> alk(en/yn)ylsulfanyl-C<sub>1-6</sub>-alk(en/yn)yl or C<sub>3-8</sub>-cycloalk(en)yl;

R<sup>10</sup> is H, C<sub>1-6</sub>-alk(en/yn)yl, aryl, aryl-C<sub>1-6</sub>-alk(en/yn)yl, wherein aryl is optionally substituted with a halogen, CF<sub>3</sub>, OCF<sub>3</sub>, CN, NO<sub>2</sub> or C<sub>1-6</sub>-alk(en/yn)yl; or an alkali  
15 metal;

or a salt thereof, such as a pharmaceutically acceptable salt.

2. The compound of claim 1 wherein X is selected from O or CH<sub>2</sub>.

20 3. The compound of any one of claims 1-2 wherein Y is O.

4. The compound of any one of claims 1-2 wherein Y is S.

5. The compound of any one of the preceding claims wherein R<sup>1</sup> is selected from  
25 hydrogen, C<sub>1-6</sub>-alkyl, halogen, phenyl, or phenyl substituted with one or two substituents selected from C<sub>1-6</sub>-alkyl or C<sub>1-6</sub>-alkoxy.

6. The compound of any one of the preceeding claims wherein R<sup>2</sup> is selected from  
hydrogen; cyano; C<sub>1-6</sub>-alkyl; halogen; phenyl; phenyl substituted with one or two  
30 substituents selected from cyano, C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkoxy, or C<sub>1-6</sub>-alkylsulfonyl; –NR<sup>13</sup>R<sup>14</sup> wherein R<sup>13</sup> and R<sup>14</sup> together with the nitrogen form a 3-7-membered heterocyclic ring which optionally contains one further heteroatom selected from O, S

or N, such as morpholinyl, or piperidinyl; or monocyclic heteroaryl, such as pyrimidinyl.

7. The compound of any one of the preceeding claims wherein R<sup>3</sup> is selected from hydrogen; C<sub>1-6</sub>-alkyl; halogen; phenyl; phenyl substituted with one or two substituents selected from cyano, C<sub>1-6</sub>-alkyl, or C<sub>1-6</sub>-alkoxy; or monocyclic heteroaryl, such as thiophenyl.

8. The compound of any one of the preceeding claims wherein R<sup>4</sup> is selected from hydrogen, C<sub>1-6</sub>-alkyl, halogen, phenyl or phenyl substituted with one or two substituents selected from C<sub>1-6</sub>-alkyl or C<sub>1-6</sub>-alkoxy.

9. The compound of any one of the preceeding claims wherein R<sup>5</sup> is phenyl, optionally substituted with a halogen, C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkyloxy, C<sub>1-6</sub>-alkylsulfanyl, halo-C<sub>1-6</sub>-alkyl.

10. The compound of any one of the preceeding claims wherein R<sup>6</sup> is selected from H or C<sub>1-6</sub>-alkyl.

11. The compound of any one of the preceeding claims wherein R<sup>7</sup> is selected from H or C<sub>1-6</sub>-alkyl.

12. The compound of any one of the preceding claims wherein R<sup>8</sup> is selected from H, C<sub>1-6</sub>-alkyl or C<sub>3-8</sub>-cycloalkyl.

13. The compound of any one of the preceding claims wherein R<sup>9</sup> and R<sup>9'</sup> are independently selected from H or C<sub>1-6</sub>-alkyl.

14. The compound of any one of the preceding claims wherein R<sup>10</sup> is H.

15. The compound of any one of claims 1-9 or 14 wherein R<sup>6</sup> and R<sup>8</sup> together with the nitrogen form a 1-pyrrolidinyl, 1-piperidinyl or 1-azepinyl, optionally substituted with a C<sub>1-6</sub>-alkyl, and R<sup>7</sup> is selected from H, C<sub>1-6</sub>-alk(en/yn)yl or C<sub>3-8</sub>-cycloalk(en)yl, and

R<sup>9</sup> and R<sup>9'</sup> are independently selected from H, C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub> alk(en/yn)ylsulfanyl-C<sub>1-6</sub>-alk(en/yn)yl or C<sub>3-8</sub>-cycloalk(en)yl.

16. The compound of any one of claims 1-9 or 14 wherein R<sup>7</sup> and R<sup>8</sup> together with the nitrogen form a 1-pyrrolidinyl, 1-piperidinyl or 1-azepinyl, optionally substituted with a C<sub>1-6</sub>-alkyl, and R<sup>6</sup> is selected from H, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub>-alk(en/yn)ylloxy, C<sub>1-6</sub>-alk(en/yn)ylsulfanyl or C<sub>3-8</sub>-cycloalk(en)yl, provided that when R<sup>6</sup> is selected from C<sub>1-6</sub>-alk(en/yn)ylloxy or C<sub>1-6</sub>-alk(en/yn)ylsulfanyl then X is CR<sup>11</sup>R<sup>12</sup>, wherein R<sup>11</sup> and R<sup>12</sup> independently are selected from H or C<sub>1-6</sub> alkyl, and R<sup>9</sup> and R<sup>9'</sup> are independently selected from H, C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub> alk(en/yn)ylsulfanyl-C<sub>1-6</sub>-alk(en/yn)yl or C<sub>3-8</sub>-cycloalk(en)yl.

17. The compound of any one of claims 1-9 or 14 wherein R<sup>8</sup> and R<sup>9</sup> together with the nitrogen form a 1-pyrrolidinyl, 1-piperidinyl or 1-azepinyl, optionally substituted with a C<sub>1-6</sub>-alkyl, and R<sup>6</sup> is selected from H, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub>-alk(en/yn)ylloxy, C<sub>1-6</sub>-alk(en/yn)ylsulfanyl or C<sub>3-8</sub>-cycloalk(en)yl, provided that when R<sup>6</sup> is selected from C<sub>1-6</sub>-alk(en/yn)ylloxy or C<sub>1-6</sub>-alk(en/yn)ylsulfanyl then X is CR<sup>11</sup>R<sup>12</sup>, wherein R<sup>11</sup> and R<sup>12</sup> independently are selected from H or C<sub>1-6</sub> alkyl, and R<sup>7</sup> is selected from H, C<sub>1-6</sub>-alk(en/yn)yl or C<sub>3-8</sub>-cycloalk(en)yl, and R<sup>9'</sup> is selected from H, C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub> alk(en/yn)ylsulfanyl-C<sub>1-6</sub>-alk(en/yn)yl or C<sub>3-8</sub>-cycloalk(en)yl.

18. The compound of claim 1 selected from  
(S)-1-{2-[2-(4-Fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,  
(S)-1-{2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,  
(S)-1-{2-[2-(4-Trifluoromethyl-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,  
(S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,  
(S)-{2-[2-(4-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,  
(S)-1-{2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,

- (S)-1-{2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- 5 (S)-1-{2-[2-(3-Chloro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[2-(4-Chloro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[2-(4-Methoxy-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[2-(3,4-Difluoro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- 1-{2(R/S)-[2-(4-Chloro-phenoxy)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,
- 10 1-{2(R/S)-[2-(3,4-Difluoro-phenoxy)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,
- (S)-1-{2-[2-(3-Fluoro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- 1-{2(R/S)-[2-(3-Fluoro-phenoxy)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,
- 1-{2(R/S)-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-propyl}-pyrrolidine-2(S)-
- 15 carboxylic acid,
- 1-{2(R/S)-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,
- ({2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)-acetic acid,
- 2-{3-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,
- 20 ({2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,
- ({2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,
- {2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy-methyl]-piperidin-1-yl}-acetic acid,
- ({2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,
- 25 {4-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-piperidin-1-yl}-acetic acid,
- (N-2-propyl-{2-[2-(4-trifluoromethyl-phenylsulfanyl)-phenoxy]-ethyl}-amino)-acetic acid,
- ({2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)-acetic acid,
- (N-Ethyl-{2-[2-(4-methylsulfanyl-phenylsulfanyl)-phenoxy]-ethyl}-amino)-acetic
- 30 acid,
- 2-{3-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,
- (S)-{3-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-acetic acid,

- ( {2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-ethyl }-N-ethyl-amino)-acetic acid,  
(N-2-propyl- {2-[2-(4-methylsulfanyl)-phenylsulfanyl)-phenoxy]-ethyl }-amino)-acetic acid,  
5 {3-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl }-acetic acid,  
( {2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-ethyl }-N-ethyl-amino)-acetic acid,  
( {2-[2-(4-Chloro-phenylsulfanyl)-phenoxy]-ethyl }-N-methyl-amino)-acetic acid,  
{4-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-piperidin-1-yl }-acetic acid,  
2- {3-[2-(4-Trifluoromethyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl }-propionic  
10 acid,  
( {2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl }-N-2-propyl-amino)-acetic acid  
( {2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl }-N-methyl-amino)-acetic acid,  
{2-[2-(4-Methylsulfanyl)-phenylsulfanyl)-phenoxy-methyl]-piperidin-1-yl }-acetic acid,  
( {2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-ethyl }-N-methyl-amino)-acetic acid,  
15 (N-Methyl- {2-[2-(4-trifluoromethyl-phenylsulfanyl)-phenoxy]-ethyl }-amino)-acetic acid,  
2- {3(R)-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl }-propionic acid,  
2- {3(R)-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl }-propionic acid,  
2- {3(R)-[2-(4-methylphenyl)-sulfanyl)-phenoxy]-pyrrolidin-1-yl }-propionic acid,  
20 {3(R)-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl }-acetic acid,  
2- {3(R)-[2-(4-Trifluoromethyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl }-propionic acid,  
2- {3(R)-[2-(4-Chloro-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl }-propionic acid,  
( {1-[2-(3-Chloro-phenylsulfanyl)-phenoxy-methyl]-propyl }-N-ethyl-amino)-acetic  
25 acid,  
( {1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-butan-2-yl }-N-ethyl-amino)-acetic acid,  
( {1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-butan-3-methyl-2-yl }-N-ethyl-amino)-acetic acid,  
30 ( {1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-butan-2-yl }-N-ethyl-amino)-acetic acid,  
( {1-[1-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl }-N-ethyl-amino)-acetic acid,

({1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-butan-4-methyl-2-yl})-N-ethyl-amino)-acetic acid,

({1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]propan-2-yl}-N-ethyl-amino)-acetic acid,

5 (S)-{1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-methyl-amino)-acetic acid ,

(S)-({1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-ethyl-amino)-acetic acid,

10 ({1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-ethyl-amino)-acetic acid,

({1-[2-(4-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-ethyl-amino)-acetic acid,

({1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]methyl]-propyl}-N-methyl-amino)-acetic acid,

15 ({1-[2-(4-Chloro-phenylsulfanyl)-phenoxy]methyl]-propyl}-N-ethyl-amino)-acetic acid,

(N-Ethyl-{1-[2-(3-fluoro-phenylsulfanyl)-phenoxy]methyl]-propyl}-amino)-acetic acid,

(R)-({2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-1-methyl-ethyl}-N-ethyl-amino)-acetic acid,

20 (S)-(2-{2-[2-(4-Chloro-phenoxy)-phenoxy]-propyl}-N-methyl-amino)-acetic acid,

(R)-(2-{2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-}-propyl)-N-methyl-amino)-acetic acid,

({2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-propyl}-N-methyl-amino)-acetic acid,

({2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-1-yl}-N-ethyl-amino)-acetic acid,

25 ({1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-3-methyl-butan-2-yl}-N-methyl-amino)-acetic acid,

({3-methyl-1-[2-(4-trifluoromethyl-phenylsulfanyl)-phenoxy]-butan-2-yl}-N-ethyl-amino)-acetic acid,

30 ({1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-butan-2-yl}-N-methyl-amino)-acetic acid,

(S)-(1-{2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-methyl-amino)-acetic acid,



- (S)-(2-{2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-propyl}-N-methyl-amino)-acetic acid,
- ((1-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-3-methyl-butan-2-yl)-N-ethyl-amino)-acetic acid,
- 5 (S)-({1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-methyl-amino)-acetic acid,
- ((1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-3-methyl-butan-2-yl)-N-methyl-amino)-acetic acid,
- ((1-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-3-methyl-propan-2-yl)-N-ethyl-
- 10 amino)-acetic acid,
- ((2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-propan-1-yl)-N-ethyl-amino)-acetic acid,
- ((2-[2-(4-methoxy-phenylsulfanyl)-phenoxy]-propan-1-yl)-N-Cyclohexyl -amino)-acetic acid,
- 15 { [2-(2-(4-methylsulfanyl)-phenoxy)-propan-1-yl]-N-cyclohexyl-amino}-acetic acid,
- ((2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-1-yl)-N-cyclohexyl-amino)-acetic acid,
- (S)-1-{3-[2-(3-Fluoro-phenylsulfanyl)-phenyl]-propyl}-pyrrolidine-2-carboxylic acid,
- (S)-2-({2-[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-methyl-amino)-
- 20 propionic acid,
- ((2-[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl)-methyl-amino)-acetic acid,
- (S)-1-{2-[4-Chloro-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- 25 (S)-1-{2-[3-Chloro-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[5-Chloro-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[4-Cyano-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-
- 30 carboxylic acid
- (S)-1-[2-(5-Chloro-2-phenylsulfanyl)-phenoxy]-ethyl]pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-pyrrolidine-2-carboxylic acid,

(S)-{2-[4'-Methoxy-3-(3-fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-pyrrolidine-2-carboxylic acid,

(S)-{2-[4'-Cyano-3-(3-fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-pyrrolidine-2-carboxylic acid,

5 (S)-1-{2-[4'-Cyano-4-(3-fluoro-phenylsulfanyl)-biphenyl-3-yloxy]-ethyl}-pyrrolidine-2-carboxylic acid,

(S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-5-thiophen-3-yl-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,

(S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-4-pyrimidin-5-yl-phenoxy]-ethyl}-pyrrolidine-  
10 2-carboxylic acid,

(S)-1-{2-[3-(3-Fluoro-phenylsulfanyl)-3-methanesulfonyl-biphenyl-4-yloxy]-ethyl}-pyrrolidine-2(S)-carboxylic acid,

(S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-4-morpholin-4-yl-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,

15 (S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-4-piperidin-1-yl-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,

or a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising a compound according to any one of  
20 claims 1-18 and a pharmaceutically acceptable carrier or diluent.

20. The use of a compound according to any one of claims 1-18 for the preparation of a medicament for the treatment of post-traumatic stress disorder or a disease selected from the group consisting of schizophrenia, including both the positive and the  
25 negative symptoms of schizophrenia and other psychoses, and in the improvement of cognition in conditions where the cognitive processes are diminished, i.e. Alzheimer's disease, multi-infarct dementia, AIDS dementia, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis or diseases wherein the brain is damaged by inner or outer influence, such as trauma to the head or stroke, and convulsive  
30 disorders such as epilepsy, spasticity or myoclonus.

21. A method for the treatment of a disease or disorder selected from the group consisting of post-traumatic stress disorder, the positive and the negative symptoms of

schizophrenia, including both the positive and the negative symptoms of schizophrenia and other psychoses, and in the improvement of cognition in conditions where the cognitive processes are diminished, i.e. Alzheimer's disease, multi-infarct dementia, AIDS dementia, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis or diseases wherein the brain is damaged by inner or outer influence, such as trauma to the head or stroke, and convulsive disorders such as epilepsy, spasticity or myoclonus in a living animal body, including a human, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1-18.